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Background: The epidemiology of vulvovaginal candidiasis (VVC) and such recurrent infections (RVVC) has
been difﬁcult to study as the majority of episodes of these conditions are self-treated by the women affected. In
Sweden, all pharmacies are owned by the state and all prescriptions and over-the-counter (OTC) products,
such as antifungals, are registered in a database, which offers unique possibilities to study the epidemiology of
VVC/RVVC.
Objectives: To analyze all prescriptions and OTC products purchased for therapy of VVC/RVVC and to
establish reasons for any observed variation in the sales ﬁgures.
Methods: Sales ﬁgures in the Swedish county of Ska ˚ne of antifungal drugs for therapy of VVC/RVVC were
analyzed by the aid of the ‘ACS’ database of the National Corporation of Swedish Pharmacies for the years
1990–1999. The size of the female population in the county is approximately half a million.
Results: The study showed that 93% of all antifungal drugs for VVC/RVVC were sold as OTC products. An
increase in sales of the drugs occurred until mid-1993/94, followed by a decrease until end of the study period in
1999. Demographic factors (e.g. the number of female inhabitants in the county, pharmacies and health-care
units), the pregnancy rate and pharmacy-dependent factors (such as the introduction of shelves for self-
selection of antifungal products) did not explain the observed variations in sales. Distinct short-term variations in
the number of prescriptions of ﬂuconazole and itraconazole could be explained by drugs company sales
campaigns and logistics factors in drug distribution. The sales volumes in the 33 municipalities in the county
correlated with the density of the population, which was not the case for the total number of prescriptions
made in the county during the 1990s. The variation in antifungal drug sales was similar to that of hormonal
intrauterine devices, but this was not the case for oral contraceptives. The total Swedish usage of antibiotics
showed a similar variation to that of the antifungal drugs analyzed.
Conclusion: The study stresses the limited impact on the treatment of VVC/RVVC by the medical community.
Behavior-related factors in the female population are the most likely explanation for the marked variations
found in the usage of drugs for the two conditions.
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DOI: 10.1080/10647440400003972Genital Candida infections, i.e. vulvovaginal
candidiasis (VVC), and such recurrent infections
(RVVC) are common conditions
1–3. The diag-
nosis of RVVC, if based only on history and
clinical examination, is frequently wrong
4–7. The
majority of assumed episodes of VVC and RVVC
are treated by the women themselves, without
involvement of any health-care providers. Studies
of the epidemiology of these conditions are
therefore difﬁcult to perform by conventional
means, such as the surveillance of cases seen by
health-care providers. However, analyses of the
usage of antifungal drugs aimed for therapy of
these conditions may be one way to overcome
this dilemma.
Toexplainchangesovertimeinsalesvolumesof
drugs for therapy of VVC/RVVC, not only
pharmacy-related factors (e.g. the number of
pharmacies in the area, the introduction of shelves
for self-selection of over-the-counter (OTC)
products and counseling activities) have to be
analyzed. Other factors that have to be considered
areany demographicalterations, suchaschanges in
the size of age groups of women particularly
susceptible to genital Candida infections, and also
the number of pregnancies, because pregnant
women are more commonly affected by genital
Candida infections. Changes in health insurance
systems, i.e. in drug subsidies, are other accoun-
table factors to be considered. Furthermore, sales
promotion activities by drug companies may have
aninﬂuenceonsalesvolumesofanydrug(Table1).
The present study is an extension of a previous
study
8, where we reported the sales pattern of
antifungal drugs that are almost exclusively used
for therapy of VVC and RVVC. In this second
paper, we have analyzed a number of factors that
might have had an inﬂuence on the ﬂuctuations
noted in the usage of such drugs, sold either as
prescriptions or as OTC products, in a Swedish
county (with approximately 1 million inhabitants)
during the 1990s.
MATERIALS AND METHODS
Database and analyses performed
The drugs that were available in Sweden for the
treatment of VVC/RVVC during the 1990s are
shown in Table 2. Sales data for these drugs and
the packages analyzed (which are used more or
less exclusively for therapy of genital Candida
infections in females), from all pharmacies in the
Swedish county of Ska ˚ne during the period
January 1990 to the end of November 1999,
were reported in the earlier study
8. The data
analyzed were derived from Apoteket AB’s ‘ACS’
database
9. Thus, we analyzed all packages sold for
vaginal application and all packages with one
capsule of 150 mg ﬂuconazole or with four
capsules of 100 mg itraconazole for oral intake,
i.e. packages also almost exclusively used for
therapy of VVC/RVVC. We chose to analyze
the number of packages sold, instead of Deﬁned
Daily Dose, as we wanted to study the sales of
drugs particularly used to treat VVC/RVVC. All
drugs sales are registered in the ACS database, but
in contrast to prescribed drugs, OTC product
sales cannot be analyzed as to sex and age of the
consumer (because such data are not requested
from the customer). It should be noted that only
the state-owned pharmacies in Sweden are
allowed to sell antifungal drugs.
In the present study, we report for the ﬁrst
time on the speciﬁc sales ﬁgures for azole drugs
for Kristianstad county (Table 3), which, together
with the former Malmo ¨hus county, now makes
up the county of Ska ˚ne in southern Sweden.
However, the discussion presented here refers to
the situation in the new, current county of Ska ˚ne
with its former two parts.
RESULTS AND DISCUSSION
Type of drugs available during the study period
The drugs most commonly used in the manage-
ment of VVC and RVVC belong to the group of
azole compounds
10–12. The azoles used for
vaginal application in Ska ˚ne, during the whole
or part of the study period, were clotrimazole
(Canesten
1), econazole (Pevaryl
1) and micona-
zole (Daktar
1) (Table 2). Econazole held two-
thirds of the market. Fluconazole (Diﬂucan
1) and
itraconazole (Sporanox
1) were used for general
therapy of VVC/RVVC and held more than 90%
of the market of oral drugs for anti-Candida
therapy.
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women for self-treatment
The packages of Pevaryl Depot
1, Pevaryl and
Canesten (all aimed for vaginal use) sold OTC in
the ﬁve administrative health districts in Ska ˚ne
county during January–December 1999 are
shown in Figure 1. The ﬁgures refer to the sales
volumes in the ﬁve different districts, per 1000
female inhabitants 15–45 years of age. The
relative proportions of these products purchased
were similar in the ﬁve districts. This indicates
that there was no difference in local pharmacy/
drug prescriber’s policies or in consumer usage
habits with regard to selection of the different
OTC azole products available.
Demographic factors
The size of the consumer group most likely to use
drugs for VVC/RVVC therapy, i.e. women of
childbearing age, is one of the factors that can
inﬂuence sales ﬁgures of antifungal drugs. How-
ever, the female population in Ska ˚ne county
remained unchanged during the study period
(Figure 2). This was also true for the age
distribution of the female inhabitants. Thus, this
demographic factor is not likely to explain the
Table 1 Factors that may inﬂuence usage of antifungal drugs in an area over time, with special reference to Candida
infections of the genital tract
Demographic No. of persons in the area who are particularly susceptible to genital fungal
infections, i.e. age distribution of the population
No. of pregnancies per study period
Health-care providers No. of doctors and midwives (prescribing or recommending antifungal drug use) in the area
and clients No. of gynaecological and youth clinics in the area
No. of women assumed by health providers to be affected by VVC/RVVC
Women assuming themselves to be infected by Candida
Health-seeking behavior of affected women
Economy Patient’s private economy
Allocation of society resources to health care
Provision of drug cost by general or private health insurance programs
Area epidemiology No. of persons with VVC and RVVC
No. of HIV-infected persons
No. of women with bacterial vaginosis
No. of individuals with uncontrolled diabetes
No. of immunocompromised patients
No. of cases in intensive care
Pharmacy-dependent No. of pharmacies displaying OTC products for self-service
Counseling activities at pharmacies
Price of drugs
Drug company initiatives Information campaigns by visits to pharmacies and physicians
Advertising directed to prescribers
Advertising of OTC products directed to the general population
Use of drugs and other Intimate hygiene products
products Oral contraceptives
Hormonal IUDs
Sexuality Age of sexual debut
Frequency of partner changes
Sexual practice
Clothing Synthetic materials in underwear
Tight-ﬁtting garments
VVC, vulvovaginal candidiasis; RVVC, recurrent VVC; HIV, human immunodeﬁciency virus; OTC, over-the-counter; IUD, intrauterine device
Antifungal drugs for therapy of genital Candida infections: 2 Ma ˚rdh et al.
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY . 101observed change in usage pattern of the drugs
studied. As pregnancy is associated with an
increased rate of VVC/RVVC episodes, changes
in the number of pregnant women during the
study period is another factor that can alter the
usage pattern. The deliveries in Ska ˚ne county
showed a continuous decrease during the 1990s
(with some minor deviations from the trend for
two separate years), i.e. from 14677 deliveries in
1990 to 8241 in 1999. Thus, neither is this factor
likely to explain the changes in sales volumes over
the study period.
Usage of antifungal drugs in rural and urban
areas
The number of prescriptions of ﬂuconazole and
itraconazole in relation to the number of women
aged 15–55 years in 1999, in the 33 different
municipalities in Ska ˚ne county, are illustrated in
Figure 3a. The various municipalities in the
county showed great variation in the sales ﬁgures
for these drugs, even after adjustment for the age
of their populations. In comparison, the sales of all
medical drugs to women aged 15–45 years in the
municipalities didnot show any such trend (Figure
3b). That is, usage of medical drugs, in general,
was not higher in the mainly urban than in the
mainly rural areas of the county. The variations in
sales volumes of antifungal drugs that are available
only by prescription could not be explained by
differences in the ease with which potential
customers accessed to health-care units. Health-
seeking behavior of urban and rural populations
may also differ; inhabitants in the former areas may
more often consult for problems considered less
serious, like genital Candida infections.
Differences between the various geographic
areas in Ska ˚ne county with respect to the number
of immigrants and second-generation immigrants
might have contributed to some of the differences
observed in the usage pattern of antifungal drugs
between the various municipalities (with most
sales in the most densely populated areas), because
pregnancies are more common in these groups
than among other inhabitants in Ska ˚ne county.
Most immigrants live in the most densely
populated municipalities in Ska ˚ne such as Malmo ¨
city, which is the largest city in the county and
where approximately one-third of all children are
born to women with an immigrant background.
Pharmacy-dependent issues and drug subsidies
The Swedish pharmacies are all state-owned and
are the only commercial source of antifungal
Table 2 Antifungal drugs, used mainly for therapy of genital Candida infections in women, that were available in Swedish
pharmacies during the 1990s
Clotrimazole (Canesten
1) 1% and 10% vaginal cream, pessaries at 100, 200 and 500 mg, and combination package with
300 or 500 mg pessaries and 1% cream
Econazole (Pevaryl
1) 1% vaginal cream, pessaries at 50 and 150 mg, and combination package with 150 mg pessaries and
1% cream. Econazole was also available as Pevaryl Depot
1 as pessaries of 150 mg and in a combination package with
such pessaries and 1% cream
Miconazole (Daktar
1) 2% vaginal cream and pessaries at 150 mg
Fluconazole (Diﬂucan
1) 150 mg capsules
Itraconazole (Sporanox
1) 100 mg capsules
Table 3 Sales in Kristianstad county, Sweden, of three
azole drugs used more or less exclusively for therapy of
vulvovaginal candidiasis and such recurrent infections for
the period January 1990 to November 1999
Drug
Year A B C
1990 19633 7337 18008
1991 19926 6605 22924
1992 20036 5932 26116
1993 12803 4321 45229
1994 12524 3555 53432
1996 14833 2662 47860
1997 13204 2027 44667
1998 12933 1869 43465
1999 11221 1573 40459
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county remained the same throughout the
1990s, at approximately 100. The pharmacies in
Ska ˚ne displaying OTC products for customers
remained unchanged during this period. This was
also true for counseling activities for antifungal
OTC products (Landgren and colleagues, unpub-
lished data).
Sales promotion activities for drugs for VVC/
RVVC therapy, appealing directly to potential
groups of female consumers, was allowed by
Swedish health authorities during the study
period, e.g. by advertisements in the tabloid press
for female readers. ‘Drug committees’ run by local
health authorities could have had an impact on
sales ﬁgures only for prescriptions, not for the
bulk of products used for these indications, as they
were sold OTC.
During the 1990s, there were a number of
changes to medical drug subsidies nationally in
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Figure 1 Sales volumes in 1999 of azoles prescribed per 1000 female inhabitants in the ﬁve administrative health
units in the county of Ska ˚ne, Sweden
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to be paid for all prescriptions made for a patient
at a given occasion. Thereafter, the sum to be paid
was calculated from the actual price of the drug(s)
prescribed, with a maximum of 1300 SEK
(*$US125, based on the exchange rate in
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Figure 3 Correlation between density of the female population aged 15–50 years in 1999 in the 33 municipalities in
Ska ˚ne county, Sweden, and the usage of (a) ﬂuconazole and itraconazole and (b) all medical drugs sold by prescription
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are age-standardized
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society. The costs for consultation with a
physician increased in Sweden in 1997. This
may have added to the costs for women who
consulted for genital Candida infections and
thereby indirectly have affected purchases of
prescribed antifungal drugs. After 1999, the cut-
off level for a 100% drug subsidy increased to
1800 SEK for each 12-month period. If a patient
concomitantly was prescribed drugs for other
conditions, the actual cost for her antifungal
therapy may even have become free during a 12-
month period. Furthermore, as OTC products
constitute the bulk of drugs used, subsidies are not
likely to have inﬂuenced the consumption pattern
studied.
Age of sexual debut and sexual practice
VVC and RVVC are rare conditions before
menarche but increase rapidly in rate after the
sexual debut
3. It is therefore likely that the age of
sexual debut in an area may inﬂuence the
consumption of antifungals used to treat these
conditions.However,nomarkedchangeintheage
of sexual debut was seen during the study period.
Sexual practice may also have an impact on the
prevalence of VVC/RVVC. In a study of female
university students, practice of oral sex was the
factor that most markedly differentiated those
with and without a history of genital Candida
infection
13. In a study of women with a history of
RVVC and with an assumed new attack of the
condition, we did not ﬁnd a correlation between
practice of either oral or anal sex and colonization
by Candida of genital and extragenital sites
14.
Concomitant infections and vaginal ﬂora changes
The very few, i.e. 116, females in Ska ˚ne county
reported infection by human immunodeﬁciency
virus (HIV) during the entire 1990s, and so
concomitant HIV infection could not have had
any great inﬂuence on total usage of vaginal
antifungal products. VVC/RVVC is also a late
phenomenon in HIV-infected women (who are
not on ‘stop medication’). The common switch
from C. albicans to non-albicans strains, seen in
esophagitis in HIV-infected patients, does not
seem to take place in the vagina of HIV-infected
women, which would have constituted a ther-
apeutic challenge.
There has been a marked and continuous
reduction in the incidence of bacterial vaginosis
(BV) in Ska ˚ne county over the study period. BV
may protect against VVC, because the amines
released from anaerobes occurring in high
numbers in the vagina in this condition might
inhibit germ tube formation in Candida
15, which
seems to be a prerequisite for mycosal invasion by
Candida fungi
16. Extracellular matrix proteins also
seem to promote persistance of Candida in the
female genital tract. Treatment of BV with
metronidazole is followed by VVC in approxi-
mately every tenth case, which may favor the
assumption of a protective role of anaerobes
against the development of VVC/RVVC.
Use of hygiene products and certain clothing
New trends in behavior may promote VVC and
RVVC. For example, use of certain intimate
hygiene products and changes in clothing and of
the material used in underwear, as well as laundry
practices of such clothes
3, could explain the
increase in usage of antifungal drugs at the
beginning of the 1990s, but is an unlikely
explanation for the decrease later on. Lycra
1
and other synthetic materials in underwear, which
cannot be washed at temperatures that kill
Candida organisms, were introduced onto the
Swedish market on a large scale during the study
period and could have inﬂuenced the rate of
RVVC. However, this is not likely to have had
any major impact on antifungal drugs sales, as sales
of such underwear did not decline during the
latter part of the 1990s. The wearing of tight
trousers and underwear has been considered to
trigger VVC/RVVC, although scientiﬁc support
for this hypothesis is still lacking
3. The increased
fashion of using string panties became more
common during the latter part of the decade,
i.e. when the sales of antifungals went down.
Clinical diagnostic dilemma
Women with RVCC were unskilled to correctly
diagnose their disease. Sihro and co-workers
17
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women assuming themselves to be suffering
from RVVC. In addition, these authors found
that almost half of such women did not properly
use the antifungal drugs that had been prescribed
to them by their physician. In the study, using
written case scenarios, 34.5% of women with a
previous episode of VVC and only 11% of these
without such an experience (P50.001) could
properly differentiate this condition from others
affecting the genital tract, such as pelvic
inﬂammatory disease, trichomoniasis and cystitis.
Women with a medical or paramedical profes-
sion more often recognized VVC correctly
(83.7%) than did women without such training.
As also indicated in the study by Garcia and
associates
18, syndrome-based management of
genital infections is difﬁcult. Pharmacy personnel
often failed to recommend the proper therapy
for sexually transmitted diseases. An educational
intervention program in pharmacies only mar-
ginally improved the quality of counseling, and
the effect was only temporary
18. To overcome
this problem, integration of courses on infectious
gynecological disorders into both basic and
postgraduate training of pharmacists should be
implemented. However, another recent study
19
illustrated that counseling at pharmacies could
reduce the patient’s need for re-consultation
with a physician. The usage of OTC products
for VVC/RVVC may, as mentioned, also be
related to the fact that these diagnoses are
difﬁcult to establish
4–7. Approximately half of
all cases with symptoms associated with VVC/
RVVC are Candida culture-negative. However,
azole preparations sold for vaginal application
often have a positive effect even if Candida
cannot be detected, through their additives of
anti-pruritus and anti-inﬂammatory effects.
One threat to optimal healthcare posed by
uncontrolled access to antifungal OTC products
could be reduction in the early detection of
carriers of sexually transmitted infectious agents
and of patients with genital cancer or precancer-
ous conditions, wrongly assumed to be RVVC.
Symptoms such as itching and discharge, which
are common in VVC and RVVC, may also occur
in those suffering from such other conditions. For
example, itching is one of the most common
complaints in chlamydia infections. It is of note
that genital chlamydial infections decreased over
the study period in the county and therefore did
not mirror the trend of azole products usage.
Concomitant drug use
Contraceptives use, i.e. of estrogen- and gesta-
gens-containing products, may have inﬂuenced
the prevalence of VVC/RVVC and thereby the
sales of antifungals. The oral contraceptives
market did increase by 20% in Ska ˚ne during the
1990s. However, the constant addition of new
contraceptives onto the market during this period
makes it difﬁcult to establish the impact of each
such drug on the epidemiology on genital
Candida infections. Thus sales of oral contra-
ceptive drugs did not mirror those of antifungal
drugs. As already mentioned elsewhere
8, neither
did the prescription of hormone replacement
therapy in the county during the 1990s change
sales volumes in the manner found for the
antifungal drugs studied.
Some drugs are known to be ‘non-antibiotic
antibiotics’, i.e. to have an antibacterial effect
apart from that of their main action
20. However,
their effect on fungi is still unknown. For
example, non-steroidal anti-inﬂammatory drugs,
like ibuprofen, not only have an antifungal effect
but also act synergistically with ﬂuconazole
21.
The sales of antibiotics in Sweden increased up
to the middle of the 1990s and decreased
thereafter
22 (Figure 4). In 1999, the consumption
level was equal to that of 1983. Thus, the trend
roughly paralleled the usage of antifungal drugs
seen in Ska ˚ne over the study period. Therefore,
antibiotics use could be one factor that may have
had at least a marginal impact on sales of drugs for
VVC/RVVC. Intensive therapy with some anti-
biotics may result in overgrowth of Candida in the
vagina. Antifungal drugs are often prescribed by
some gynecologists when prescribing a broad-
spectrum antibiotic to a woman to counteract the
risk that she will develop VVC.
Women with RVVC were signiﬁcantly more
likely to suffer clinical depression, to be less
satisﬁed with life, to have poor self-esteem and to
perceive their lives as more stressful than were
controls
23. Whether the massive use of antide-
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antifungals remains, however, to be proved.
CONCLUSIONS
Despite analyzing a large number of factors in
an attempt to explain why there were such
marked changes in the usage of antifungal drugs
for therapy of VVC/RVVC in Ska ˚ne during
the 1990s, it was not possible to identify any
single factor or even combination of factors that
could be responsible. Neither is it likely that
the usage pattern mirrored a change in the
epidemiology of genital Candida infections;
conditions not considered to be contagious
(not representing sexually transmitted condi-
tions). The common usage of OTC products
aimed for VVC/RVVC therapy may be an
overconsumption related to the fact that these
diagnoses are difﬁcult to establish. Approxi-
mately half of all such assumed cases are
negative in laboratory tests for Candida.
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